The stock of Intellia Therapeutics Inc (NTLA) has gone down by -10.57% for the week, with a -14.44% drop in the past month and a -13.32% drop in the past quarter. The volatility ratio for the week is 5.85%, and the volatility levels for the past 30 days are 5.31% for NTLA. The simple moving average for the last 20 days is -9.35% for NTLA stock, with a simple moving average of -23.85% for the last 200 days.
Is It Worth Investing in Intellia Therapeutics Inc (NASDAQ: NTLA) Right Now?
The 36-month beta value for NTLA is at 1.76. Analysts have varying views on the stock, with 1 analysts rating it as a “buy,” 3 rating it as “overweight,” 2 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for NTLA is 99.78M, and currently, shorts hold a 14.79% of that float. The average trading volume for NTLA on October 02, 2024 was 1.38M shares.
NTLA) stock’s latest price update
The stock price of Intellia Therapeutics Inc (NASDAQ: NTLA) has plunged by -6.57 when compared to previous closing price of 20.55, but the company has seen a -10.57% decline in its stock price over the last five trading sessions. globenewswire.com reported 2024-10-01 that CAMBRIDGE, Mass., Oct. 01, 2024 (GLOBE NEWSWIRE) — Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that interim data from the ongoing Phase 1 study of nexiguran ziclumeran (nex-z, also known as NTLA-2001) will be presented in a late-breaking oral presentation at the 2024 American Heart Association (AHA) Scientific Sessions, taking place November 16 – 18 in Chicago, Illinois. Nex-z is an investigational in vivo CRISPR-based gene editing therapy designed to be a single-dose treatment for transthyretin (ATTR) amyloidosis. Intellia leads development and commercialization of nex-z as part of a multi-target discovery, development and commercialization collaboration with Regeneron. The presentation will include safety, reduction in serum TTR and biomarkers of disease progression, and functional capacity data in patients with ATTR amyloidosis with cardiomyopathy (ATTR-CM).
Analysts’ Opinion of NTLA
Many brokerage firms have already submitted their reports for NTLA stocks, with Goldman repeating the rating for NTLA by listing it as a “Neutral.” The predicted price for NTLA in the upcoming period, according to Goldman is $32 based on the research report published on February 23, 2024 of the current year 2024.
Canaccord Genuity gave a rating of “Buy” to NTLA, setting the target price at $66 in the report published on April 13th of the previous year.
NTLA Trading at -15.39% from the 50-Day Moving Average
After a stumble in the market that brought NTLA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -44.94% of loss for the given period.
Volatility was left at 5.31%, however, over the last 30 days, the volatility rate increased by 5.85%, as shares sank -11.19% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -24.20% lower at present.
During the last 5 trading sessions, NTLA fell by -10.57%, which changed the moving average for the period of 200-days by -36.82% in comparison to the 20-day moving average, which settled at $21.06. In addition, Intellia Therapeutics Inc saw -37.03% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at NTLA starting from Clark Eliana, who sale 405 shares at the price of $22.93 back on Jul 01 ’24. After this action, Clark Eliana now owns 71,470 shares of Intellia Therapeutics Inc, valued at $9,287 using the latest closing price.
Verwiel Frank, the Director of Intellia Therapeutics Inc, sale 1,505 shares at $25.00 during a trade that took place back on Jun 17 ’24, which means that Verwiel Frank is holding 17,948 shares at $37,625 based on the most recent closing price.
Stock Fundamentals for NTLA
Current profitability levels for the company are sitting at:
- -11.4 for the present operating margin
- 0.79 for the gross margin
The net margin for Intellia Therapeutics Inc stands at -11.07. The total capital return value is set at -0.48. Equity return is now at value -49.02, with -40.46 for asset returns.
Based on Intellia Therapeutics Inc (NTLA), the company’s capital structure generated 0.1 points at debt to capital in total, while cash flow to debt ratio is standing at -3.51. The debt to equity ratio resting at 0.11. The interest coverage ratio of the stock is -59.33.
Currently, EBITDA for the company is -506.21 million with net debt to EBITDA at 0.05. When we switch over and look at the enterprise to sales, we see a ratio of 41.89. The receivables turnover for the company is 3.73for trailing twelve months and the total asset turnover is 0.04. The liquidity ratio also appears to be rather interesting for investors as it stands at 7.21.
Conclusion
In conclusion, Intellia Therapeutics Inc (NTLA) has had a bad performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
